Johnson, Douglas B. http://orcid.org/0000-0002-6390-773X
Menzies, Alexander M.
Article History
First Online: 11 April 2023
Competing interests
: D.B.J. has served on advisory boards or as a consultant for Bristol Myers Squibb, Catalyst Biopharma, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer, Targovax and Teiko; has received research funding from Bristol Myers Squibb and Incyte; and has patents pending for use of MHC class II as a biomarker for immune-checkpoint-inhibitor response, and abatacept as treatment for immune-related adverse events. A.M.M. has served on advisory boards for Bristol Myers Squibb, MSD, Novartis, Pierre-Fabre, QBiotics and Roche.
Free to read: This content has been made available to all.